Cite
HARVARD Citation
Seftel, M. et al. (2017). The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Leukemia & lymphoma. 58 (6), pp. 1358-1365. [Online].